Gen-Probe Incorporated (NASDAQ: GPRO) announced that it recently has been granted seven additional patents by the U.S. and European patent authorities that extend the Company’s intellectual property estate related to automated instrument systems for nucleic acid testing (NAT).

The newly granted patents relate to automated sample preparation and target nucleic acid amplification, as well as closed-tube sampling.  The patents complement an extensive portfolio of 65 patents previously granted to Gen-Probe that relate to automated instrument systems for nucleic acid testing.

"These important new patents extend an already strong intellectual property estate surrounding automated instrumentation for molecular diagnostics, and further acknowledge the pioneering work our R&D team has done on behalf of our customers," said Bill Bowen, Gen-Probe’s senior vice president and general counsel.
Gen-Probe’s TIGRIS® system is the first and only integrated, fully automated, high-throughput nucleic acid testing system for clinical diagnostics and blood screening.

Source: Gen-Probe, Inc